Diversify Advisory Services LLC Grows Position in Astera Labs, Inc. $ALAB

Diversify Advisory Services LLC lifted its stake in Astera Labs, Inc. (NASDAQ:ALAB) by 32.4% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 14,263 shares of the company’s stock after buying an additional 3,489 shares during the quarter. Diversify Advisory Services LLC’s holdings in Astera Labs were worth $2,596,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of ALAB. Vanguard Group Inc. lifted its position in shares of Astera Labs by 14.1% in the third quarter. Vanguard Group Inc. now owns 13,743,141 shares of the company’s stock worth $2,690,907,000 after buying an additional 1,693,918 shares in the last quarter. Amundi lifted its position in shares of Astera Labs by 1,298.6% in the third quarter. Amundi now owns 1,421,263 shares of the company’s stock worth $278,283,000 after buying an additional 1,319,643 shares in the last quarter. Rafferty Asset Management LLC purchased a new stake in shares of Astera Labs in the third quarter worth about $209,599,000. BNP Paribas Financial Markets lifted its position in shares of Astera Labs by 577.3% in the third quarter. BNP Paribas Financial Markets now owns 1,127,340 shares of the company’s stock worth $220,733,000 after buying an additional 960,899 shares in the last quarter. Finally, Voloridge Investment Management LLC purchased a new stake in shares of Astera Labs in the third quarter worth about $131,539,000. Hedge funds and other institutional investors own 60.47% of the company’s stock.

Astera Labs Price Performance

Shares of ALAB stock opened at $149.05 on Friday. Astera Labs, Inc. has a 1 year low of $52.56 and a 1 year high of $262.90. The stock’s 50 day simple moving average is $128.11 and its two-hundred day simple moving average is $155.08. The company has a market cap of $25.52 billion, a PE ratio of 122.17, a price-to-earnings-growth ratio of 2.93 and a beta of 1.78.

Astera Labs (NASDAQ:ALAB) last issued its quarterly earnings data on Tuesday, February 10th. The company reported $0.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.51 by $0.07. Astera Labs had a return on equity of 16.12% and a net margin of 25.70%.The business had revenue of $270.58 million for the quarter, compared to the consensus estimate of $249.46 million. During the same period in the prior year, the business posted $0.37 earnings per share. The company’s quarterly revenue was up 91.8% compared to the same quarter last year. Astera Labs has set its Q1 2026 guidance at 0.530-0.540 EPS. Equities research analysts expect that Astera Labs, Inc. will post 0.34 EPS for the current year.

Astera Labs News Roundup

Here are the key news stories impacting Astera Labs this week:

• Positive Sentiment: Company signals higher growth expectations and investor optimism ahead of Q1 results — investors interpreted the note as confirmation of robust demand and loaded up on shares. Astera Labs (ALAB) Eyes ‘High Double-Digit Growth,’ Soars 27%
• Positive Sentiment: Product/spec and customer wins: reports say a UALink spec upgrade plus new hyperscaler wins, which are material for Astera’s connectivity/bridge products and signal larger TAM and pull‑through for future revenue. Astera Labs (ALAB) Surges Over 13% on UALink Spec Upgrade and Hyperscaler Wins
• Positive Sentiment: Unusual options activity: traders bought ~39,399 call options (≈54% above typical call volume), a bullish signal that likely amplified intraday buying and expectations for upside around upcoming results.
• Positive Sentiment: Analyst/list support: included in recent growth‑stock roundups and cited with strong insider confidence; an aggregated analyst view is an average “Moderate Buy,” reinforcing buy‑side momentum. April 2026’s Leading Growth Stocks With Strong Insider Confidence Astera Labs, Inc. (NASDAQ:ALAB) Given Average Recommendation of “Moderate Buy” by Analysts
• Neutral Sentiment: Short interest reporting showed zero shares — likely a data/reporting artifact and not meaningful short‑pressure information at present, so it doesn’t explain the move.

Insiders Place Their Bets

In other news, General Counsel Philip Mazzara sold 10,000 shares of the stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $107.77, for a total value of $1,077,700.00. Following the sale, the general counsel owned 118,084 shares of the company’s stock, valued at approximately $12,725,912.68. This represents a 7.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jack R. Lazar sold 2,500 shares of the stock in a transaction on Monday, March 16th. The shares were sold at an average price of $130.00, for a total transaction of $325,000.00. Following the completion of the sale, the director directly owned 84,851 shares in the company, valued at approximately $11,030,630. This represents a 2.86% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 577,292 shares of company stock valued at $69,495,249. 12.50% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms recently commented on ALAB. Loop Capital began coverage on Astera Labs in a research report on Thursday, March 5th. They issued a “buy” rating and a $250.00 target price on the stock. Royal Bank Of Canada initiated coverage on shares of Astera Labs in a research note on Wednesday, January 14th. They set an “outperform” rating and a $225.00 price target on the stock. Weiss Ratings downgraded shares of Astera Labs from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, February 23rd. Barclays set a $165.00 price target on shares of Astera Labs in a research note on Thursday, January 15th. Finally, Citigroup initiated coverage on shares of Astera Labs in a research note on Thursday, April 2nd. They set a “buy” rating and a $200.00 price target on the stock. Fifteen equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Astera Labs presently has an average rating of “Moderate Buy” and a consensus target price of $199.44.

Astera Labs Profile

Astera Labs is a fabless semiconductor company that develops connectivity solutions for data center and cloud infrastructure. The firm focuses on addressing signal integrity and link management challenges that arise as server architectures incorporate higher-bandwidth processors and accelerators. Its technology is aimed at improving reliability and performance for high-speed interconnects used in servers, storage systems and compute accelerators.

The company’s product portfolio centers on silicon devices and accompanying firmware and software that enhance and manage high-speed links.